WaveSense Europe launches Jazz glucose meter in UK
26 March 2008
WaveSense Europe launched the WaveSense Jazz blood glucose monitoring
system at the 2008 Diabetes UK meeting in Glasgow this month. The blood
glucose meter (BGM) is designed to help people with diabetes gain
tighter control over their blood glucose levels.
In addition to requiring no code and having large backlit digits, the
Jazz provides a glycemic variability value. Glycemic variability is a
tool used to show how glucose changes over time and may allow the
patient or their health care professional to better analyze high and low
readings and take preventative action.
"I'm thrilled to bring our flagship product to the UK diabetes
community," said Claudio Carboni, Managing Director of WaveSense Europe
Ltd. "This market demands innovative, high accuracy, and high quality
BGM products and I feel that WaveSense Jazz is well-positioned to
advance the quality of diabetes care."
Jazz features WaveSense, a new technology that personalises each test
to provide high accuracy. It detects and corrects for errors caused by
different environmental conditions and blood samples.
"There's plenty of research showing the need for improved glucose
control, especially for those on insulin," said Dave Conn, Chief
Commercial Officer of WaveSense and former President and CEO of
Hypoguard. "WaveSense technology finally gives those with diabetes the
accurate glucose measurements they need to act with more confidence."